NantKwest

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory.

Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases.

"At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman 

NantCapital

Oberland Capital

Patrick Soon-Shiong

ImmunityBio, Inc.

Did you know? Firefighters are at a higher risk of developing cancer due to job-related carcinogen exposure. ImmunityBio is dedicated to advancing bladder cancer research, offering new treatments for these everyday heroes. Learn more at the American Cancer Society. https://lnkd.in/gtNi7wQG

ImmunityBio is looking forward to the American Urological Association (AUA) annual conference! We are excited to discuss our research, dive into insightful discussions, and connect with industry peers. Visit us in booth #1931. May 3-6, see you there! https://auanet.org/AUA2024 

On the National Mall stand more than 27,400 flags representing people under the age of 50 projected to be diagnosed with Colon Cancer in 2030, a cancer highly associated with Lynch Syndrome. Learn about our Lynch Syndrome cancer prevention efforts: https://lnkd.in/djjBtnwV

Friday, March 22nd, was Lynch Syndrome Awareness Day. ImmunityBio is dedicated to advancing research for early detection and treatment for this disease. Together, we can bring hope and change to the thousands of Americans with the Lynch syndrome genetic mutation. Learn more: https://lnkd.in/djjBtnwV

ImmunityBio is advancing research to end bladder cancer. Join us and the Bladder Cancer Advocacy Network (BCAN) to fight bladder cancer in the Walk to End Bladder Cancer. Every step you take makes a difference. Learn more about how you can participate: https://lnkd.in/gAsvzVT7

IPhone / Mobile Compatible

Google Tag Manager

HSTS

WordPress

Global Site Tag

DoubleClick.Net

US Privacy User Signal Mechanism

DMARC

Organization Schema

Chief Strategy Officer

Fabio Benedetti MD

General Counsel and Corporate Secretary

Jason Liljestrom

Chief Technology Officer at ImmunityBio

Kayvan Niazi

Leonard Sender

Chief Communications Officer (CCO)

Sarah Singleton

Chief Scientific Officer

Shahrooz Rabizadeh

Marketing and Product

Elizabeth Gabitzsch

Vice President, Quality

Israel Palmer

Vice President of Product Development, Cell Therapy Program

Manju Saxena

Vice President of Biometrics

Paul Bhar

Founder and Executive Chairman

Barry Simon

Director & Chief Corporate Affairs Officer

Dora Gruner

Senior Corporate Development Counsel

Chief Communications Officer

Helen Luu

Chief Commercial Officer

Charles Kim

General Counsel

Fabio Benedetti

Enrique Diloné

Chief Technology Officer

Health Diagnostics Companies With Less Than $1B in Revenue (Top 10K)

Greater Los Angeles Area Companies With More Than $50M in Revenue

Western US Companies With More Than $10M in Revenue (Top 10K)

Western US Companies With More Than 500 Employees (Top 10K)

NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks.

Post-IPO Equity - ImmunityBio

Post-IPO Debt - ImmunityBio

Private Equity Round - ImmunityBio

Culver City

California

United States

North America

ImmunityBio

ImmunityBio extends gains after trial update

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Cash-crunched ImmunityBio, on heels of FDA nod for Anktiva, lays off staffers

ImmunityBio lays off workers in Louisville

ImmunityBio: Anktiva’s Launch Demands A Reassessment (NASDAQ:IBRX)

ImmunityBio Loses Bid to Dodge Investor Suit Over Drug Rejection

ImmunityBio spikes after commercial update on lead drug Anktiva

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

ImmunityBio, LadRx end licensing deal for cancer drug

ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Czech Republic

Europe

Hong Kong

Asia

India

Colombia

South America

HTML5

Fonts.com

Bootstrap

Google Maps API

jQuery

Wordpress

GoDaddy Premium DNS

Vimeo

Google Fonts

Google Analytics

Prokarium is a biopharmaceutical company specializing in microbial immunotherapy for oncology applications.

Prokarium

EpiVax Inc is involved in immuno-oncology and cytotoxic T-cell-based cancer immunotherapy.

EpiVax Inc

Cellectis is a biopharmaceutical company focused on developing immunotherapies for cancer treatment.

Cellectis

Bristol-Myers Squibb is a global biopharmaceutical company that develops and delivers innovative medicines for patients with serious diseases.

Bristol-Myers Squibb

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need.

Gilead Sciences

Autolus is a biopharmaceutical company focused on the development and commercialization of next-generation, programmed T cell therapies for the treatment of cancer.

Autolus

City of Hope is a leading research and treatment center for cancer, diabetes, and other life-threatening diseases.

City of Hope

Innovative Cellular Therapeutics is a company focused on developing innovative cellular therapies for the treatment of cancer.

Innovative Cellular Therapeutics

Celularity is a biotechnology company focused on developing and commercializing novel cellular therapies for cancer treatment.

Celularity

ImmunityBio is a clinical-stage immunotherapy company that develops next-generation therapies that aim to address the patient's immune system. The company's research and development efforts are focused on novel treatments for cancer, infectious diseases, and autoimmune diseases.

news impact assignment basic	general
public peers	general	May 14, 2024 7:42 AM	52fa9a6f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	a5714aa6
crunchbase profile	general	Oct 30, 2024 2:36 PM	d5cc6f2d
li profile	general	May 14, 2024 7:42 AM	de372b80
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	9e2876f6
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:IMMUNITYBIO

ImmunityBio